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In order to derive mice which expressed both the E7 open reading frame transgene of human papillomavirus type 16 in
skin and MHC class 1 restriction elements for several E7-encoded cytotoxic T-lymphocyte (CTL) epitopes, K14.HPV16E7 mice
which express E7 in basal keratinocytes were crossed to the F1 generation with A2.1 Kb transgenic mice which express the
MHC binding cleft domains of human HLA A*0201, and murine H-2b. F1 mice (denoted K14E73A2.1) expressed E7 in the
thymus at least as early as 2–5 days before birth. Immunisation of FVB3A2.1 control mice (transgenic for HLA A*0201 and
H-2b but not for E7), with two HLA A*0201-restricted epitopes of E7 and one H-2b-restricted CTL epitope of E7, gave strong
primary CTL responses recognising epitope-pulsed or constitutively E7-expressing syngeneic target cells. In contrast, in
immunised K14E73A2.1 mice, the CTL responses to the H-2b epitope and one of the HLA A*0201 CTL epitopes were strongly
down-regulated, and to the other HLA A*0201 epitope, completely abolished, as demonstrated by percentage specific killing
by bulk splenocyte cultures in cytotoxicity assays, and by CTL precursor frequency analysis. In thymus-transplanted bone
marrow radiation chimeras in which the immune system of K14E73A2.1 mice was replaced by a FVB3A2.1 immune system,
specific immunisation did not result in reemergence of strong E7-directed CTL responses. In agreement with these in vitro
findings, specific immunisation failed to significantly alter the course of E7-associated tumour development in K14E73A2.1
mice. These data are consistent with a model of central deletional CTL tolerance to E7-encoded epitopes recognised in the
context of two distinct MHC class 1 restriction elements, and with the possibility of peripheral T-cell anergy maintained by
expression of E7 in the skin. © 1998 Academic Press
INTRODUCTION
The E7 oncoprotein of human papillomavirus type 16
(HPV16) contributes to the transformation and mainte-
nance of malignant phenotype in epithelial cells in vitro
(von Knebel Doerberitz et al., 1994; Munger, 1995), and
presumably also in E7 expressing premalignant and ma-
lignant lesions of the uterine cervix. HPV16 is associated
with up to 90% of cervical squamous cell neoplasms
(Bosch et al., 1995). Continued expression of E7 to main-
tain the transformed phenotype (von Knebel Doeberitz et
al., 1994) thus provides a tumour-associated antigen to
which immunomanipulative strategies can be directed
(Tindle et al., 1995). A high percentage of cervical carci-
noma patients make antibody to HPV16 E7 (Bleul et al.,
1991), and E7 directed cytotoxic T-lymphocytes have
been detected in some (Altmann et al., 1992; Ressing et
al., 1996) as a result of endogenous expression of E7.
Vaccination with HPV16 E7 induces cellular and humoral
immunity in humans (Borysiewicz et al., 1996) and in
animal models, with protection against challenge with
E7-expressing tumour detected in the latter (Chen et al.,
1993; Tindle et al., 1995).
The phenotypic sequelae of expression of an HPV E7
transgene in the epithelium of mice are diverse depend-
ing (at least in part) on the promoter used and the site of
expression of the transgene within the epithelium. Mice
expressing HPV16 E6 and E7 or E7 alone specifically in
the basal or suprabasal epithelial cells driven from ker-
atin 10 or keratin 14 promoters (Arbeit et al., 1994;
Auewarakul et al., 1994; Herber et al., 1996; Melero et al.,
1997) display epithelial hyperplasia and dysplasia at mul-
tiple epidermal and squamous mucosal sites with a
propensity to papillomatosis and squamous cell carci-
noma, particularly at sites subject to mechanical or
chemical irritation (Coussens et al., 1996). Such mice
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provide a model for E7-mediated epithelial cell transfor-
mation in humans (Frazer et al., 1995) and for testing of
E7-directed immunopreventative and immunotherapeutic
interventions (Tindle, 1996). In addition, these mice pro-
vide a model with which to probe fundamental immuno-
logical questions regarding presentation of neoantigen
(E7) to the immune system by cells of epithelial origin.
We have previously shown that mice with constitutive
expression of E7 restricted to epithelium in adult life, and
without perinatal expression in the thymus (Griep et al.,
1993), had no endogenous E7-directed CTL response,
and generated specific cytotoxic T-lymphocyte (CTL) fol-
lowing E7 immunisation in a way indistinguishable from
their non-E7 transgenic counterparts (Herd et al., 1997).
In addition, these mice generated no antibodies to en-
dogenous E7 unless skin wounding or local invasive
tumours occurred, as a consequence of which E7 pre-
sentation to the immune system presumably occurred in
professional antigen-presenting cells as well as in epi-
thelium (Frazer et al., 1995).
In this paper, we investigate the primary E7-directed
CTL responses induced by immunisation in mice derived
from the K14.HPV16E7 transgenic line (Herber et al.,
1996), in which expression of the E7 transgene is driven
from the keratin 14 promoter and occurs in basal epithe-
lial cells. Since previous work from our group has shown
that the H-2q background of these mice does not provide
a restriction element for any E7-derived CTL epitope
(Herd et al., 1997), we crossed K14.HPV16E7 mice to the
F1 generation with HLA A*0201 transgenic mice (Vitiello
et al., 1991), thereby introducing CTL restriction elements
for three defined E7 CTL epitopes (two HLA A*0201-
restricted epitopes (Ressing et al., 1995) and one H-2Db-
restricted epitope (Feltkamp et al., 1993)).
We demonstrate that E7 is expressed in the thymus
before birth in K14E73A2.1 mice. We show that, in im-
munised K14E73A2.1 mice, CTL responses to two of the
three CTL epitopes are down-regulated, and to one
epitope, abolished, in these E7 transgenic mice com-
pared to their non-E7 transgenic counterparts. In the
case of at least one CTL epitope, down-regulation is due
to a loss of CTL precursors across a wide range of
CTL–MHC/peptide complex affinities. We demonstrate
that the residual CTL response induced by specific im-
munisation in K14E73A2.1 mice fails to protect them
from development of E7-associated tumours. Ablation of
the immune system by whole body irradiation abolished
completely the residual CTL response in K14E73A2.1
mice. The capacity to mount non-E7 transgenic levels of
CTL activity could not be established in these ablated
mice by adoptive reconstitution with thymus implants
and immunocytes, both from syngeneic but non-E7
transgenic donors. The results are discussed within the
context of central thymic tolerance induction and of
maintenance of peripheral CTL nonreactivity to E7 in
K14E73A2.1 mice.
RESULTS
Perinatal thymic expression of E7 in K14E73A2.1
mice
We demonstrated E7 mRNA in the thymus of K14E73A
2.1 mice at least as early as 2–5 days before birth, and in
neonates at 8 days (Fig. 1).
The CTL response to a H-2b-restricted CTL epitope is
down-regulated in K14E73A2.1 mice
Groups of K14E73A2.1 and FVB3A2.1 mice were
immunised with various doses of 8Q peptide, contain-
ing the H-2Db-restricted E7 CTL epitope RAHYNIVTF.
Splenocytes from FVB3A2.1 mice specifically killed
EL4.A2 cells pulsed with peptide 8Q, and EL4 cells
expressing the E7 gene (C2 cells) irrespective of
immunising dose used in the experiment (Figs. 2A–
2C). In comparison, the percentage specific cytotoxic-
ity against EL4.A2 cells pulsed with 8Q, and against
C2 cells, was significantly lower in corresponding
groups of K14E73A2.1 mice immunised with 50 and 10
mg of 8Q peptide, and specific killing was not detected
in K14E73A2.1 mice immunised with 0.4 mg of 8Q
(Figs. 2D–2F).
The CTL responses to two HLA A*0201-restricted
CTL epitopes are down-regulated or abolished in
K14E73A2.1 mice
Splenocytes from K14E73A2.1 and FVB3A2.1 mice
immunised with 50 mg each of a mixture of peptides 597
FIG. 1. RT–PCR detects perinatal expression of E7 RNA in the thymus
of K14E73A2.1 mice. Lane 1, lambda DNA MW markers; Lane 2,
pJ4VE7 plasmid (positive control); Lane 3, RNA from thymus 2–5 days
before birth, with RTase; Lane 4, RNA from thymus 2–5 days before
birth, without RTase; Lane 5, RNA from thymus 8 days after birth, with
RTase; Lane 6, RNA from thymus 8 days after birth, without RTase.
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and 598, were restimulated in vitro with 597 or 598. CTL
activity was measured against EL4.A2 target cells pulsed
with cognate or irrelevant (in this case 8Q) peptide.
FVB3A2.1 splenocytes restimulated with 597 or 598
showed high specific killing of EL4.A2 targets pulsed
with 597 or 598, respectively (Figs. 3D and 3B).
K14E73A2.1 splenocytes restimulated with 597 showed
no killing of 597 pulsed EL4.A2 targets (Fig. 3C).
K14E73A2.1 splenocytes restimulated with 598 showed
killing of 598 pulsed EL4.A2 targets (Fig. 3A). No killing
by any group was observed on 597 or 598 pulsed EL4
cells (data not shown), indicating that CTL killing was
mediated through the HLA A*0201 restriction pathway.
K14E73A2.1 mice are competent to make CTL
responses
Spleen cells from K14E73A2.1 mice and FVB3A2.1
mice immunised with influenza matrix peptide displayed
comparable levels of killing EL4.A2 cells pulsed with
cognate peptide (percentage specific killing at 50:1 ef-
fector:target cell ratio, 55.72 1/2 2.88% and 56.63
1/21.97%, respectively). Similarly, spleen cells from
K14E73A2.1 mice and FVB3A2.1 mice immunised with
ovalbumin both displayed killing of EG7.OVA cells which
constitutively express ovalbumin (percentage specific
killing at 50:1 effector:target cell ratio, 22.501/20.63%
and 51.801/21.45%, respectively), but not EL4 cells.
These observations rule out a constitutive defect in
K14E73A2.1 mice to make CTL responses restricted
through the HLA A*0201 or the H-2b pathways, respec-
tively, as the cause of the highly down-regulated E7-
directed CTL responses displayed by K14E73A2.1 mice.
The frequency of E7-specific CTL precursors is
diminished in K14E73xA2.1 mice
We wished to determine whether the frequency of CTL
precursors was reduced in E7 epitope-immunised E7
transgenic mice when compared with their identically
immunised non-E7 transgenic counterparts. Figure 5 in-
dicates that the frequency of E7-specific CTL precursor
cells capable of expansion by specific in vitro restimu-
lation, and lysis of cognate peptide-coated targets, was
significantly lower in the spleens of 8Q-immunised
K14E73A2.1 mice than the frequency of such precursors
in the spleens of 8Q-immunised FVB3A2.1 mice.
Peptide requirements for sensitising target cells for
killing by K14E73A2.1-derived CTL and FVB3A2.1-
derived CTL
We wished to determine whether immunised E7-trans-
genic mice would generate E7-directed CTL with less
affinity for cognate epitope than immunised non-E7
FIG. 2. CTL responses of splenocytes from mice immunised with various doses of 8Q peptide, and restimulated with 8Q peptide in vitro. (A–C)
FVB3A2.1 mice; (D–F) K14E73A2.1 mice. Triangles, C2 cells; solid squares, EL4.A2 cells pulsed with 8Q peptide; open squares, EL4.A2 cells pulsed
with 597 (irrelevant) peptide.
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transgenic mice. Figures 4A and 4B show a more-or-less
constant lower level of killing by effectors from
K14E73A2.1 mice compared with effectors from
FVB3A2.1 mice irrespective of concentration of peptide
epitope used to sensitise the targets. However, data
presented in Fig. 5 indicate that (at least for 8Q-directed
FIG. 3. CTL responses of splenocytes from mice immunised with peptides 597 and 598, and restimulated with either peptide 597 (C,D) or 598 (A,B)
in vitro. (A and C) K14E73A2.1 mice; (B and D) FVB3A2.1 mice. Open squares, EL4.A2 cells pulsed with peptide 598; open triangle, EL4.A2 cells pulsed
with peptide 597; closed squares, EL4.A2 cells pulsed with 8Q (irrelevant) peptide; closed diamond, unpulsed EL4.A2 cells.
FIG. 4. Cytotoxicity of splenocytes from FVB3A2.1 mice (open squares) and K14E73A2.1 mice (closed squares) against EL4.A2 target cells pulsed with
varying concentrations of cognate peptide. Three mice were used per mouse strain per peptide. (A) In vitro restimulated splenocytes from mice immunised
with peptide 598; (B) in vitro restimulated splenocytes from mice immunised with peptide 8Q. The effector:target ratio in both A and B was 50:1.
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CTL) the number of E7 epitope-specific precursor CTLs
is 10- to 20-fold higher in FVB3A2.1 mice than in
K14E73A2.1 mice. Were the data in Fig. 4 normalised to
equivalent numbers of E7-specific CTL in the FVB3A2.1
and K14E73A2.1 effector populations, then the difference
in cytotoxic efficacy between effectors from the two types
of mice would disappear. Thus, the data in Fig. 4 suggest
that the residual effective E7-directed precursor CTL
population, which remains in K14E73A2.1 mice, has a
spread of affinities for cognate epitope 1 MHC essen-
tially similar to that seen in the FVB3A2.1 mice where the
E7-directed precursor CTL population is intact.
Reconstituted (manipulated) K14E73A2.1 mice
acquire FVB3A2.1-derived CD4 and CD8 T cells
We wished to inquire whether the high levels of CTL
activity seen in immunised FVB3A2.1 non-E7 transgenic
mice would be observed were we to ablate the thymus
and immune system of K14E73A2.1 mice and replace it
with thymus and immune system from FVB3A2.1 mice.
We presumed that the K14E73A2.1 T-cell system had
been centrally tolerised with respect to E7 in the E7-
expressing K14E73A2.1 fetal thymus. The immune sys-
tem of K14E73A2.1 was ablated by thymectomy and
whole body irradiation followed by injection of anti-
Thy1.1-depleting antibody to remove radioresistant T-cells.
The mice were reconstituted with FVB3A2.1 bone marrow
(BM) cells depleted of CD41 and CD81 cells, and a thymus
implant of FVB3A2.1 origin. When tested 1 week after
irradiation and BM reconstitution, the mice exhibited pro-
found peripheral leucocytopenia. At 6 weeks post-BM re-
constitution (4 weeks postthymus implant), the peripheral
leucocytopenia was reversed but the mice had not re-
gained circulating peripheral CD4 and CD8 cells (Figs. 6A
and 6B). At 11 weeks post-BM-reconstitution, CD4 and
some CD8 cells were detected in the periphery (Figs. 6C
and 6D), and by 14 weeks CD4 and CD8 cells in the
periphery had returned to levels approximately 50% of
those of sham-manipulated control mice (Figs. 6E and 6F).
Further examination of these manipulated mice revealed a
vascularised cellular subcapsular renal thymus graft con-
taining CD4/CD8 double positive cells and quantitatively
normal spleen cellularity (not shown). The E7 gene could
not be detected by PCR in DNA from peripheral blood
FIG. 6. CD4 and CD8 populations in peripheral blood mononuclear
cells of (I) manipulated K14E73A2.1 mice at 6 (A,B), 11 (C,D), and 14
weeks (E,F) after bone marrow reconstitution, and (II) sham-manipu-
lated K14E73A2.1mice (G,H). CD4 and CD8 populations are gated.
FIG. 5. Precursor frequency estimates for E7-directed CTL recovered
from the spleens of FVB3A2.1 mice (open squares) and K14E73A2.1
mice (closed triangles) immunised with peptide 8Q. Data on the pro-
portion of nonresponding cultures versus number of splenocytes per
culture is linearly regressed (solid line), and enclosed by 95% confi-
dence limits (dotted lines), determined by the least squares method. f,
precursor frequency estimate.
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mononuclear cells (PBMC) of manipulated mice, but was
readily detectable in DNA from PBMC of sham-manipulated
mice, indicating that that the leucocyte compartment had
been reconstituted by cells of FVBxA2.1 origin (Fig. 7).
A T-cell system of FVB3A2.1 origin fails to establish
a ‘‘nontolerant’’ level of E7-directed CTL in the
manipulated K14E73A2.1 mice
Splenocytes from sham-manipulated K14E73A2.1
mice immunised with peptides 597 and 598, and restim-
ulated with 597 and 598 showed significantly down-
regulated killing of EL4.A2 cells pulsed with cognate
peptide, compared with similarly immunised sham-ma-
nipulated FVB3A2.1 mice (Figs. 8A and 8B). This residual
response was lost completely in the manipulated
K14E73A2.1 mouse examined 6 weeks after reconstitu-
tion (Fig. 8C), when no circulating CD41 or CD81 cells
were detectable in the periphery (Figs. 6A and 6B). The
CTL response did not reestablish in 597 and 598 immun-
ised manipulated K14E73A2.1 mice 16 weeks after re-
constitution with FVB3A2.1 bone marrow (12 weeks after
FVB3A2.1 thymus), even though E7 gene negative CD41
and CD81 cells (i.e., of FVB3A2.1 origin) constituted the
peripheral T-cell pool (Figs. 6E and 6F, and Fig. 7, Lanes
2 and 3).
A T-cell system of FVB3A2.1 origin reestablishes CTL
responses to non-E7 antigen in manipulated
K143A2.1 mice
To establish that functional reconstitution of CTL
responses had occurred, spleen cells from manipu-
lated K14.E73A2.1 mice immunised with a mix of the
three E7 peptide epitopes and influenza matrix
epitope, were reacted with groups of EL4.A2 target
cells pulsed with individual E7 peptides or influenza
matrix peptide. Figure 8, II shows that the reconsti-
tuted mice displayed CTL responses to the influenza
matrix CTL epitope, but not to any of the three E7 CTL
epitopes. This indicates that the capacity to mount
CTL responses to non-E7 antigen had been restored
by FVB3A2.1 thymus and bone marrow grafting, and
confirms that CTL responses could not be established
against the three CTL epitopes of E7 origin.
Multiple immunisation of K14E73A2.1 mice with
peptides encoding E7 CTL epitopes fails to prevent
the development of E7-associated tumours or induce
E7-directed CTL responses
CTLs directed to the E7 oncoprotein have been shown
to specifically abrogate the growth of challenge doses of
E7-expressing transplantable tumours (Feltkamp et al.,
1993; Tindle et al., 1995). We wished to inquire whether
the residual E7-directed CTL response elicited by im-
munisation would ameliorate the development and
growth of induced E7-associated tumours in K14E73A2.1
mice. Florid E7-associated papillomas developed in
K14E73A2.1 mice, beginning at ca. weeks 9–10 after
commencement of the tumour-inducing regimen.
K14E73A2.1 mice typically had 20–40 macroscopic pap-
illomatous tumours and 0–few sebaceous tumours on
the shaved dorsal surface exposed to tumour induction.
(In contrast, non-E7 transgenic FVB3A2.1 mice devel-
oped 0–few tumours of any kind). We sought to (a) delay
the appearance of tumours and/or abrogate the extent of
tumour growth in K14E73A2.1 mice by multiple immuni-
sation both before and during tumour induction, with
peptides encoding E7 CTL epitopes, and (b) quantify CTL
responses in these mice. Groups of K14E73A2.1 mice
were immunised seven times with 8Q, or with 597/598, or
with whole E7 fusion protein or with ı´rrelevant peptide.
Tumour induction commenced after the fourth immuni-
sation. In all groups tumours first appeared at 9 to 10
weeks after commencement of tumour induction, and
progressively increased in number until the experiment
was terminated (to prevent distress to the mice) at 19
weeks. Intergroup comparisons of the number of tu-
mours were made during weeks 16–19, inclusive. The
irrelevantly immunised mice developed a mean of 22.7
tumours per mouse at 16 weeks, increasing to 29.7 at
week 19 (Fig. 9C). The number of tumours per mouse at
weeks 16–19 did not differ significantly from the irrele-
vantly immunised group among mice immunised with 8Q
(x2 5 7.8, df 5 7, P , 0.1), with 597/598 (x2 5 4.3, df 5 7,
P , 0.5), or with whole E7 (x2 5 3.7, df 5 7, P , 0.5) (Figs.
9A, 9B, and 9D) (this conclusion was reached regardless
of whether actual tumour numbers, or tumour numbers
predicted from the linear regression line, were used for
statistical analysis. Actual tumour numbers were used in
the analysis given here). Similar observations were
made in a second identical experiment, though in that
case a somewhat lower (but not significantly different)
number of tumours at 16–19 weeks was recorded in
597/598 immunised mice (not shown).
CTL precursors were sought in the spleens of the
8Q-immunised mice at the end of the experiment (19
FIG. 7. Circulating PBMC of manipulated K14E73A2.1 mice do not
contain the E7 gene. PCR using primers to amplify full-length E7 and
OTC were used on total cellular DNA prepared from PBMC of individual
mice. PCR products were run on a 1% agarose gel. Lanes contain PCR
product from (Lanes 2 and 3) an individual K14E73A2.1-manipulated
mouse; (Lane 4) a K14E73A2.1 sham-manipulated mouse; (Lane 5) a
sham-manipulated FVB3A2.1 mouse; (Lane 6) a K14E73A2.1 mouse;
and (Lane 7) a FVB3A2.1 mouse. Lane 1 contains PCR product from E7
plasmid.
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FIG. 8. (I) CTL responses of splenocytes from manipulated or sham-manipulated mice immunised with an equimolar mix of peptides 597 and 598 and
restimulated with both 597 and 598 in vitro. (A) sham-manipulated K14E73A2.1; (B) sham-manipulated FVB3A2.1; (C) manipulated K14E73A2.1, 6 weeks after
bone marrow reconstitution; (D) manipulated K14E73A2.1 16 weeks after bone marrow reconstitution. EL4.A2 cells pulsed with peptide 598 (open squares),
peptide 597 (open triangle), irrelevant peptide 8Q (closed squares), and unpulsed EL4.A2 (closed triangle) (II) CTL responses of splenocytes from
manipulated K14E73A2.1mice 20 weeks after bone marrow reconstitution, immunised with an equimolar mix of 597, 598, 8Q, and influenza matrix peptides,
and restimulated with a mix of 597, 598, 8Q, and influenza peptides in vitro. EL4.A2 cells pulsed with 597 (open squares), 598 (closed squares), 8Q (open
triangle), influenza matrix peptide (open diamond), and unpulsed EL4.A2 (closed triangle). Percentage specific killing by splenocytes from influenza matrix
peptide immunised, sham-manipulated K14E73A2.1 mice was 51.44 1/2 1.76% at an effector:target cell ratio of 70:1.
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weeks). Splenocytes restimulated in vitro with cognate
peptide, from K14E73A2.1 mice immunised with 8Q,
failed to kill 8Q-loaded target cells. In contrast, spleno-
cytes from FVB3A2.1 mice which had been identically
immunised and subject to identical tumour induction,
efficiently killed 8Q loaded targets (Fig. 10). In accor-
dance with these in vivo and in vitro findings, it was
found that in vivo depletion of CD81 cells or CD41 cells,
or both CD41 and CD81 cells did not have a statistically
significant effect on the outcome of tumour development
in 8Q-, 597/598-, or E7-immunised K14E7xA2.1 mice (data
not shown).
DISCUSSION
In this study we demonstrate that the specific immuni-
sation-induced CTL response to two HPV16 E7 CTL
epitopes is reduced, and to a further epitope, abolished
completely in mice expressing the E7 transgene perina-
tally in the thymus and throughout life, in basal epithelial
FIG. 9. Linear regressions of mean cumulative papilloma counts per mouse following tumour induction in K14E73A2.1 mice immunised with (A)
peptide 8Q; (B) peptides 597 and 598; (C) irrelevant peptide; (D) E7/GST fusion protein. (Tumour induction in control FVB3A2.1 mice produced a mean
of 0.40 papillomas per mouse at 19 weeks.)
FIG. 10. CTL responses of splenocytes harvested at week 19 from mice immunised on days 0, 14, 21, and 42, and thereafter at four weekly intervals
until week 19, and in which tumour induction commenced at day 21. (A) K14E73A2.1 mice immunised with peptide 8Q; (B) K14E73 A2.1 mice
immunised with E7/GST; (C) FVB3A2.1 mice immunised with peptide 8Q. Closed squares, EL4.A2 cells pulsed with peptide 8Q; open squares, EL4.A2
cells pulsed with a mix of peptides 597 and 598; open diamond, C2 cells.
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cells. The down-regulation was seen in CTL responses
restricted by two restriction elements: H-2b and HLA
A*0201. The observation that the K14E73A2.1 mice made
CTL responses to ‘‘irrelevant’’ (i.e., non-E7) H-2b-re-
stricted (ovalbumin) and HLA A*0201-restricted (influen-
za) CTL epitopes of comparable magnitude to their
non-E7 transgenic counterparts, argues against (a) a
constitutive poorer ability to make CTL responses, and
(b) lower expression of either of the two restriction ele-
ments, in the E7 transgenic mice as explanation(s) for
the down-regulation of CTL responses to E7 epitopes
observed in our study.
The predominant tolerogenic mechanism for CTLs is
generally thought to involve intrathymic negative selec-
tion of maturing T cells with reactivity to self-peptides
presented in association with MHC-encoded molecules
on the epithelial compartment of the thymic stroma (Hoff-
man et al., 1995). A prevalent view is that T cells with high
affinity for self-peptide/MHC complex are deleted. We
observed perinatal expression of E7 driven from the K14
promoter in K14E73 A2.1 mice.The K14 promoter directs
transgene expression to thymic epithelium (Laufer et al.,
1996). Frequency analysis of E7-specific CTL precursors
in K14E73A2.1 mice and in their non-E7 FVB3A2.1 coun-
terparts indicated a major diminution of CTL precursors
in the E7 transgenic mice (Fig. 5). We suggest that this is
likely due to deletion of maturing T-cells with receptors
for cognate E7 CTL epitope in the E7-expressing devel-
oping thymus.
CTLs with reactivity to two of the E7 epitopes studied
could still be detected in the E7 transgenic mice (Figs. 2
and 3). The existence of potentially autoreactive CTLs in
the periphery is well documented in humans and exper-
imental animals (Miller et al., 1997). Presumably, these
cells escape thymus censorship by expressing antigen-
specific TcRs of too low an affinity for the self-antigen, or
there is insufficient expression of the antigen in the
thymus, or the self-epitope may not exist in the thymus as
a stable complex with MHC molecules (Miller et al.,
1997). Our data suggest that (within the context of the
peptide concentrations used) the residual populations of
E7-reactive splenic T-cells in K14E73A2.1 mice, which
are directed to the HLA A*0201 epitope 598 and the H-2b
epitope in peptide 8Q, have a similar spread of affinities
for cognate epitope 1MHC as E7-directed precursor
CTLs in FVB3A2.1 mice where the E7-directed precursor
CTL repertoire remains intact (Fig. 4).
The observation that T cells to some epitopes are
totally depleted, and to other epitopes partially depleted
leading to diminished specific T cell response, as re-
ported in this paper and in other systems (Hoffman et al.,
1992; von Herrath et al., 1994; Oehen et al., 1994), is
consistent with this mechanistic process of a central
deletional tolerance induction in the thymus, in which
some precursors avoid deletion and escape to the pe-
riphery. Our observations are also consistent with pro-
posed alternative processes in which (a) at least some
high avidity self-reactive T cells may not be deleted, but
positively selected and display effector functions of a
regulatory type in the periphery (Coutinho, 1995; Modigli-
ani et al., 1996), and (b) at least some lower affinity/
avidity interactions may lead to clonal inactivation (unre-
sponsiveness) of T cells exported to the periphery (Kawai
and Ohashi 1995).
Multiple immunisation of K14E73A2.1 mice with ei-
ther E7 CTL peptide epitopes or whole E7 protein
failed to significantly control the development of in-
duced E7-associated skin tumours, and this correlated
with a lack of E7-specific CTL responses in these
mice. The apparent ineffectiveness of cellular immune
response in control of tumour development in such
mice was underscored by lack of effect of depletion of
CD81 or CD41 cells, or CD81 and CD41 cells on
tumour development. These observations are sup-
ported by experiments (G. Fernando et al., submitted
for publication) which demonstrated that (K14E73
C57BL)F1 mice failed to control a challenge with syn-
geneic E7-expressing tumour following immunisation
with peptide containing the H-2b-restricted CTL epitope
(RAHYNIVTF), whereas in identically immunised non-E7
transgenic (FVB3C57BL) F1 mice, the tumours did not
establish. This in vivo finding correlated with the induc-
tion of RAHYNIVTF-specific CTLs in (FVB3C57Bl)F1
mice but not in (K14E73C57Bl)F1 mice.
K14E73A2.1 mice in which the lymphopoietic system
and mature T-cells had been ablated, and which had
been reconstituted with a FVB3A2.1 lymphopoietic sys-
tem, whose T-cells had matured through a FVB3A2.1
(i.e., non-E7 transgenic) thymic graft, (manipulated mice),
failed to acquire the E7-directed CTL responses typical
of FVBxA2.1 mice, following immunisation with E7 pep-
tide epitopes. (That these mice were functionally recon-
stituted for CTL responses was confirmed by the capac-
ity to mount influenza matrix peptide (i.e., non-E7)-di-
rected CTL responses.) Nor were there overt signs of
skin-directed autoimmunity in (unimmunised) manipu-
lated mice. This begs the question whether the donor
(FVB3A2.1) T-cells were anergised peripherally by E7
expressed in host (K14E73A2.1) epithelium. Evidence
from other systems indicates that tolerance to ‘‘self’’ an-
tigens is maintained by peripheral as well as central
(thymic) mechanisms (reviewed in Miller et al., 1997).
Processed self peptides (in this case E7 peptides) pre-
sented at the keratinocyte surface in the context of MHC
class 1 in the absence of appropriate second signals
(B7.1/CD28,CTLA) may be tolerogenic rather than immu-
nogenic (Bal et al., 1990; Miller et al., 1997). Evidence that
E7 expression in epithelium stimulates neither the affer-
ent nor the efferent arms of the immune system, for a
positive response, is accumulating. Thus, E7-containing
full-thickness skin grafts from E7 transgenic mice to
syngeneic non-E7 transgenic recipients were not re-
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jected, even following prior E7 immunisation of the re-
cipients to generate demonstrable E7-specific CTL re-
sponses (Dunn et al., 1997). The questions of whether E7
expression in epithelium can induce specific peripheral
immune unresponsiveness, and whether the persistence
of E7 expression in skin throughout life is necessary to
maintain the down-regulation of E7-directed CTL re-
sponses which we observe in K14E73A2.1 mice, are
currently being addressed in our laboratory. These ques-
tions have implications for the development and persis-
tence of both endogenous- and vaccine-induced E7-
directed immune responses in epithelially derived
HPV16-associated cervical cancer in humans, since a
majority of these cancers express E7 constitutively.
In H-2b mice expressing HPV16 E6 and E7 off the
keratin 14 promoter in skin and neonatal thymus, Melero
and co-workers observed no down-regulation of the CTL
response induced by immunisation with E7 peptide
epitope RAHYNIVTF, and concluded that the mice re-
mained immunologically ignorant of this CTL epitope
(Melero et al., 1997). This result stands in contrast to
ours, and the reason(s) for the difference is not immedi-
ately apparent. The expansion of CD81 precursors in
mice is enhanced by Freund’s adjuvant, as used by the
Melero group, with the possibility of ‘‘bystander killing’’
(Doherty, 1995). An alternative explanation is that, unlike
the K14E73A2.1 mice used in our experiments, the E7
gene in their mice was expressed as a fusion with the E6
gene, with possible implications for antigen processing
and presentation of E7 CTL epitopes in the thymus.
Another possibility that a more complete restimulation
occurred in their system by using cells expressing whole
E7 for in vitro restimulation of splenocytes from immun-
ised mice is unlikely to explain the difference in results,
since CTL tolerance has been observed in spleens of E7
transgenic mice restimulated with E7-expressing synge-
neic cells (I. Jochmus, personal communication).
MATERIALS AND METHODS
Mice
K14.HPV16E7 mice are FVB (H-2q) mice made germ-
line transgenic for a DNA fragment containing HPV16
sequence from nt 79–883 and engineered to transcribe
E7-specific mRNA driven from the human keratin (K14)
promoter which is restricted in its activity to the stratum
basale of epithelium (Herber et al., 1996).
Transgenic A2.1Kb mice express a chimeric HLA class
1 molecule composed of the a-1 and -2 domains of HLA
A*0201, and the a-3 transmembrane and cytoplasmic
domains of H-2Kb (Vitiello et al., 1991), on a predomi-
nantly C57Bl (H-2b) background.
In the experiments reported here, male K14.HPV16E7
mice were crossed with female A2.1Kb mice. All parents
were homozygous for their respective transgenes. The
F1 offspring were designated K14E73A2.1. They dis-
played a characteristic phenotype of stunted growth,
wrinkled skin as newborns and striated fur as adults, and
pycnotic eyes with cataracts characteristic of K14 pro-
moter-driven epithelial E7 expression. The presence of
the E7 gene was confirmed by PCR. HLA A*0201 was
expressed in the epithelium as determined by immuno-
cytochemistry using Mab MA2.1 (ATCC, MD). F1 control
mice (designated FVB3A2.1) were obtained by crossing
male FVB mice with female A2.1Kb mice. Founder mice
were derived by caesarean section, and all mice were
housed under specific pathogen-free conditions. Genetic
authenticity was tested at intervals. Mice were used at
7–15 weeks of age, but within a given experiment were
littermates or closely age and sex matched.
Expression of the E7 gene in perinatal thymus
Messenger RNA was extracted from thymuses removed
from fetal mice at 2–5 days before birth, or newborn mice at
8 days after birth using the poly(A) tract system (Promega
Corp.) and was analysed by RT–PCR. E7 transgene-specific
cDNA was synthesised using reverse transcriptase (Super-
script II, Gibco) and subsequently amplified by Taq poly-
merase using E7 oligonucleotide primers, representing nt
562–582 (59-ATGCATGGGATACACCTACA-39) and 858–887
(59-TGGTATAGATCTGGTGATTATGGTTT-39) of the HPV16
sequence, in the presence of RNA-ases H and T1 (Boeh-
ringer and Gibco, respectively). Bands corresponding to
full-length E7 were detected on a 1% agarose gel. Amplified
E7 DNA from plasmid pJ4VE7 was used as positive control.
Detection of E7 gene in PBMCs
PBMCs were extracted from the retro-orbital blood by
hypotonic lysis of erythrocytes. Cellular DNA was ex-
tracted from 107 PBMC using a QIAamp tissue kit (QIA-
GEN Pty. Ltd). Approximately 550 ng was amplified for 35
cycles by PCR using E7 primers (above) to generate
full-length product which was detected as a band on a
1% agarose gel. Lane loading was standardised by par-
allel amplification of ornithine carboxylase (OTC).
Peptides and epitopes
Peptides representing fragments of the HPV16 E7 pro-
tein were synthesised with free ends using 9-fluorenyl-
methoxycarbonyl (F-moc) chemistry and analysed by
HPLC by Chiron Corp. Peptide 8Q (44QAEPDRAHYNIVT-
FCCKCD62) contains the H-2Db-restricted CTL epitope
49RAHYNIVTF 57 (Feltkamp et al., 1993), and an overlap-
ping T-helper epitope 48DRAHYNI54 (Tindle et al., 1991).
Peptides 597 and 598 (86TLGIVCPI93 and 82LLMGTL-
GIV90, respectively) constitute HLA A*0201-restricted
CTL epitopes (Ressing et al., 1995). Peptide 58GILG-
FVFTL66 is a HLA A*0201-restricted influenza A matrix
protein CTL epitope (Gotch et al., 1987). Peptide stocks
were made at 10 mg/ml in dimethyl sulphoxide and
diluted into tissue culture medium for assays.
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Cell lines
The cell line designated C2 was derived from EL4 cells
(a H-2b thymoma) transfected to stably express the full-
length HPV16 E7 gene (Tindle et al., 1995). The cell line
EL4.A2 was derived by transfecting EL4 with a plasmid
containing the A2.1Kb gene and a hygromycin selection
marker (Vitiello et al., 1991). Following antibiotic selec-
tion, and passage at low cell density, HLA A*0201 cell
surface expression was confirmed in EL4.A2 cells by
flow cytometry (FACS IV, Becton–Dickinson & Co.) using
Mab MA2.1 and F(ab’)2-anti mouse IgG/FITC (Caltag)
secondary reagent. All cells in the EL4.A2 cell line dis-
played a log increase in fluorescence intensity, indicat-
ing a high level of HLA A*0201 a-1 and a-2 chain ex-
pression. EL4.A2 cells are susceptible to specific CTL
lysis through both the H-2b and the HLA A*0201 path-
ways. Ovalbumin-expressing EG7.OVA cells were de-
rived from EL4 cells by transfection with a full-length
ovalbumin gene (Moore et al., 1988). Cell lines were
maintained in Dulbecco’s modified eagles minimal es-
sential medium (DMEM, Gibco) supplemented with 2
mM glutamine, 1 mM sodium pyruvate, 20 mM HEPES,
5 3 1025 M b-mercaptoethanol, 100 IU/ml penicillin, 100
mg/ml streptomycin, and 10% foetal bovine serum (FBS).
Induction and measurements of CTL responses
In standard experiments, groups of three mice were
immunised once with 50 mg of 8Q peptide, or 50 mg each
of a mixture of 597 and 598 peptides, plus 10 mg of Quil
A adjuvant (Fossum et al., 1990), in 100 ml PBS, subcu-
taneously at the base of the tail. Mice receiving the
597/598 mixture also received 2.5 mg of tetanus toxoid
(TT) (CSL Ltd.) as a source of a T-helper epitope(s). Ten
days later, spleens were removed and splenocytes were
restimulated in vitro for 6 days in 24-well tissue culture
plates (3 3 106 to 5 3 106 cells per well) in the presence
of 1 mg per ml of cognate peptide. CTL assays were
conducted as previously described (Herd et al., 1997). In
summary, target cells (104 per well) sensitised at 37°C
for 1 h with 1 mg/ml cognate or irrelevant peptide, or
expressing the E7 gene, and labelled with 100 mCi
51chromium (Cr), were incubated with effector cells at
various effector:target ratios in triplicate in 96-well mi-
crotitre plates. Negative controls included wells contain-
ing targets but no effectors (background). In positive
controls for CTL responses to non-E7 antigen, mice were
immunised with 50 mg of ovalbumin or influenza matrix
peptide, plus Quil A. Spleen cells from these mice were
restimulated in vitro with irradiated EG7.OVA cells or
cognate peptide, respectively, and CTL responses were
measured against EG7.OVA or influenza matrix peptide-
pulsed EL4.A2 cells. Supernatants were harvested from
CTL assays at 4 h, and 51Cr release was quantified by
gamma counting. Results are expressed as percentage
cytotoxicity (51Cr release in experimental wells minus
background/detergent-mediated total release minus
background) 3 100%. In experiments to determine the
affinity of CTL in bulk cultures of effectors from immun-
ised E7 transgenic and non-E7 transgenic mice, the
target cells were coated with varying concentrations of
cognate peptide from 10 to 0.0001 mg/ml. The target cells
were then reacted with effector cells in standard CTL
assays as above.
Radiation chimeras
Radiation chimeras were made following the tech-
nique of Bertolino et al. (1995). In summary, K14E73A2.1
mice were thymectomised at 4–5 weeks of age, lethally
irradiated with 1000 rad at 7–8 weeks, and reconstituted
on the same day with 5 3 106 to 5 3 107 bone marrow
cells depleted of CD41, CD81, and Thy1.21 cells (see
below) from FVBxA2.1 donors. One day after reconstitu-
tion, the mice were injected intraperitoneally with 100 ml
of complement fixing anti-Thy1 ascitic fluid to remove
radioresistant cells. After 2 weeks, they were grafted
under the kidney capsule with a thymus lobe from a
newborn FVB3A2.1 mouse. Mice were rested for a num-
ber of weeks before analysis of PBMC for absence of the
E7 gene and for presence of surface expression of CD4
and CD8 by flow cytometry, using monoclonal antibodies
GK1.5 and 2.43, respectively (hybridomas from ATCC).
These mice are referred to as ‘‘manipulated mice.’’ Con-
trol ‘‘sham-manipulated’’ mice underwent surgical proce-
dures, without the cell/organ transfers.
Bone marrow cells for transplant
Long bones were flushed with DMEM 1 2.5% FBS, the
cells were washed twice, and were incubated at 5 3 107
cells per ml for 30 min at 4°C with a mixture of anti-CD4,
anti-CD8, and anti Thy 1.2 antibodies. Cells were then
incubated at 5 3 107 cells per ml in DMEM 110% FBS
plus rabbit complement (C-Six Diagnostics Inc.) for a
further 45 minutes at 37°C. Following three washes, the
cells were injected intravenously in a volume of 100 ml.
Flow cytometry
Approximately 106 cells were reacted with primary
antibody or control antibody for 45 min on ice. After three
washes, cells were stained with F(ab’)2 anti-mouse IgG/
FITC (Caltag) or anti-rat IgG/FITC (Caltag) as appropriate
for a further 45 min on ice in the dark. Following further
washes, analysis was performed on a FACS IV (Becton–
Dickinson), gated accordingly.
CTL Precursor (CTLp) frequency
CTLp frequencies were determined as described pre-
viously (Tripp et al., 1995). One hundred microlitres of
dilutions of responder cells in medium were added to
round-bottom wells of a microtitre plate. Twenty repli-
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cates were plated for each dilution and cocultured with
106 2500-rad gamma-irradiated syngeneic spleen cells in
100 ml plus cognate peptide at 1 mg/ml. Human r-IL-2
(GIBCO/BRL) was added to 25 units/ml. Cultures were
incubated for 7 days at 37°C in a humidified atmosphere.
At the end of the culture period, individual cultures were
divided in half, and incubated for 4 h with 51Cr-labelled
EL4.A2 cells either pulsed with cognate peptide, or with-
out cognate peptide. Estimates of CTLp frequency were
obtained by interpolation from Poisson distribution fre-
quency as the linearly regressed slope of the line when
the numbers of negative cultures were plotted against
number of responder cells per well, with 95% confidence
intervals of the frequency estimate.
Tumour induction and promotion
Parental strain K14.HPV16E7 mice homozygous for the
E7 transgene spontaneously develop two types of skin
tumour late in life, namely highly keratotic lesions repre-
senting low grade squamous carcinomas (papillomata),
and cystic sebaceous epitheliomas (Herber et al., 1996).
In contrast, K14E73A2.1 F1 mice used in the present
study, which are hemizygous for E7, do not spontane-
ously develop skin tumours. This may represent a gene
dosage effect since, in multiple lines of K14.HPV16 E7
mice, penetrance of phenotype correlated with levels of
E7 gene expression (Herber et al., 1996). Thus, tumours
were induced on the shaved dorsal surface of
K14E73A2.1 mice by application of a single dose of 0.03
mM dimethylbenzanthracene (Sigma Chemical Co.) in
100 ml of acetone. Seven days later applications of the
tumour promoter 15 nM phorbol 12-myristate 13-acetate
(Sigma Chemical Co) in 100 ml acetone were made one
to two times a week. This regimen induced florid papil-
lomas expressing HLA A*0201 and E7 in K14E73A2.1
mice, but virtually no papillomas in FVB3A2.1 mice. The
regimen also induced occasional sebaceous epithelio-
mas in some K14E73A2.1 mice but these were too few in
number to be useful in analysis.
Effect of immunisation on tumour growth
Groups of six K14E73A2.1 mice in two separate ex-
periments were immunised with 50 mg 8Q 1 10 mg Quil
A, with 50 mg each of a 597/598 mixture 1 2.5 mg TT110
mg Quil A, with 50 mg irrelevant peptide 1 Quil A, or with
50 mg E7.GST fusion protein (Fernando et al., 1995) 1 10
mg Quil A, on days 0, 14, 21, and 42 and thereafter at four
weekly intervals until week 19. Tumour induction and
promotion commenced at day 21. Mice were maintained
in a shaved state. Papillomas appeared at weeks 9 and
10. The number of papillomas per mouse and per group
was quantified weekly, to 19 weeks when mice were
euthanised to prevent suffering.
CD4,CD8 T-cell subset depletion
Mice immunised on days 0, 21, and 42, and subjected
to the tumour induction regimen commencing on day 21
(as above) were injected intraperitoneally with 0.1 ml
ascitic fluid diluted 1:1 in phosphate-buffered saline of
Mab GK1.5 (anti-CD4 ), or 2.43 (anti-CD8), or a 50:50 mix
of GK1.5 and 2.43, at 3-day intervals over a 15-day period,
commencing on day 42. Effective subset depletion im-
mediately after the antibody administration regimen and
at intervals to the end of the experiment (week 12) was
confirmed by FACS analysis on PBMC.
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